Tetralogic Pharma (TLOG)
OTHER OTC:TLOG
TLOG Stock Chart & Stats
$0.01
$0.00(0.00%)
At close: 4:00 PM EST
$0.01
$0.00(0.00%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.01
Previous CloseN/A
Volume107.58K
Average Volume (3M)0.00
Market Cap
$979.00
Enterprise ValueN/A
Total Cash (Recent Filing)$5.89M
Total Debt (Recent Filing)$30.81M
Price to Earnings (P/E)―
Beta146.77
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding24,465,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
TLOG FAQ
What was Tetralogic Pharma’s price range in the past 12 months?
Tetralogic Pharma lowest stock price was <$0.01 and its highest was $0.01 in the past 12 months.
What is Tetralogic Pharma’s market cap?
Tetralogic Pharma’s market cap is $979.00.
When is Tetralogic Pharma’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Tetralogic Pharma’s earnings last quarter?
Currently, no data Available
Is Tetralogic Pharma overvalued?
According to Wall Street analysts Tetralogic Pharma’s price is currently Overvalued.
Does Tetralogic Pharma pay dividends?
Tetralogic Pharma does not currently pay dividends.
What is Tetralogic Pharma’s EPS estimate?
Tetralogic Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tetralogic Pharma have?
Tetralogic Pharma has 24,465,000 shares outstanding.
What happened to Tetralogic Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tetralogic Pharma?
Currently, no hedge funds are holding shares in TLOG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tetralogic Pharma
TetraLogic Pharmaceuticals Corporation operates as a clinical-stage biopharmaceutical firm, concentrating its efforts on identifying and advancing small-molecule treatments for cancer and infectious diseases. The company's development pipeline features two key clinical-stage drug candidates: birinapant and SHAPE. Birinapant, a small molecule, functions as a Second Mitochondrial Activator of Caspases (SMAC) mimetic, promoting programmed cell death, or apoptosis, in compromised cells. SHAPE, another proprietary compound, is a histone deacetylase (HDAC) inhibitor intended for topical administration to address early-stage cutaneous T-cell lymphoma. Furthermore, TetraLogic Pharmaceuticals has a research collaboration with the Walter and Eliza Hall Institute of Medical Research to explore the application of SMAC-mimetics, including birinapant, in treating infectious diseases. Founded in 2001 as Gentara Corporation, the company adopted its current name, TetraLogic Pharmaceuticals Corporation, in January 2006 and maintains its headquarters in Malvern, Pennsylvania.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---